Bright Green: A New Dawn in Plant-Based Controlled Substances

Bright Green Corporation (OTC: BGXX) ("Bright Green" or the "Company") has recently announced a significant restructuring, with Lynn Stockwell, the founder of the company, Drugs Made in America Acquisition Corp I, and Drugs Made in America Acquisition Corp II, aligning her vision to on-shore the end-to-end active pharmaceutical ingredient (API) manufacturing back to the United States. This strategic move is expected to position Bright Green as the facilitator and supplier of plant-based controlled substances authorized to manufacture in the United States. The restructuring plan includes the cancellation of all existing contracts, land purchase options, employment agreements, board member agreements, financing agreements, and warrants, allowing the company to realign with Ms. Stockwell's vision.

As part of the restructuring security agreement (RSA), the CEO, CFO, and Board of Directors have resigned, paving the way for Ms. Stockwell to administratively lead the restructuring. The RSA outlines her capital plans for the restructuring, ensuring that all creditors or contractors will be paid in full via a combination of cash and stock. Although creditors are impaired, the plan aims to provide a fair and equitable resolution for all parties involved.

Post-restructuring, Bright Green plans to complete a shareholder-approved reverse split and seek re-listing on a major exchange. Lynn Stockwell will continue to be the majority shareholder and a significant part of the new management team and board. The company's new business model will focus on offering supply agreements and production contracts to produce plant-based substances for the manufacturing of controlled substances, utilizing its existing registrations, licenses, and diversion control expertise for production and manufacturing.

Bright Green will also maintain its EB-5 investor program, which could provide a source of financing and attract foreign investors looking to gain U.S. residency. Additionally, the company is exploring a franchise-based business model to build agriculture facilities in phases across West Texas, East Arizona, and Central New Mexico. Each facility will include 15-acre specialty greenhouses, constructed annually until market demand is met. These facilities will benefit from high elevations, abundant resources, prearranged permits, and streamlined processes under the U.S. administration's new policies promoting billion-dollar domestic investments.

The initiative integrates the USCIS EB-5 program, allowing qualifying franchisees/owners/operators to earn U.S. Green Cards through investments that create direct and indirect jobs, meeting the program's requirements. Bright Green will manage facility development, including loan guarantees, engineering, water management, and supply contracts for agricultural production and pharmaceutical-grade controlled substances. The facilities will operate under strict legal guidelines, marking the first U.S.-based production of such substances.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management as of such date. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. Such forward-looking statements include, but are not limited to, the ability of the Company to raise funds under the Company's EB-5 program, the impact that new officers, directors, and employees may have on the Company and the Company's business and results of operations, and the impact of the New Mexico Board of Pharmacy and DEA approvals. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of risks and uncertainties.



Ms. Stockwell's vision for Bright Green is to play a vital role in supplying plant-based controlled substances to established U.S. based drug manufacturers that require domestic production to stay competitive in the new politically driven manufacturing landscape. By offering supply agreements and production contracts, Bright Green aims to facilitate and supply plant-based controlled substances authorized to manufacture in the United States, potentially strengthening its relationships with drug manufacturers in the long run.

The cancellation of existing contracts and agreements, as part of the restructuring plan, will impact ongoing projects and obligations of Bright Green. However, the company plans to provide that all creditors or contractors be paid in full via a combination of cash and stock as part of the restructuring plan. This could help to maintain relationships with key stakeholders and minimize disruptions to ongoing projects and obligations. Additionally, Bright Green plans to seek re-listing on a major exchange and offer supply agreements and production contracts to produce plant-based substances for the manufacturing of controlled substances, utilizing its existing registrations, licenses, and diversion control expertise for production and manufacturing. This could help to attract new investors and secure new contracts, offsetting the impact of the cancelled agreements.

The restructuring and new focus on plant-based controlled substances will likely enhance Bright Green's ability to attract and retain new clients in the pharmaceutical industry. The new politically driven manufacturing landscape is pushing for domestic production of controlled substances. By aligning with this trend, Bright Green will be well-positioned to supply these substances to established U.S. based drug manufacturers, making it an attractive partner for them. Bright Green's existing registrations, licenses, and diversion control expertise will be crucial in producing and manufacturing plant-based controlled substances, making it an appealing choice for pharmaceutical companies looking to outsource production. Lynn Stockwell's involvement and leadership in the restructuring process, along with her track record as the founder of Bright Green Corporation and related entities, can instill trust and confidence in potential clients. This can help Bright Green attract and retain new clients.

The changes in management and board composition, with Lynn Stockwell assuming the role of Executive Chair and CEO, are expected to significantly influence Bright Green's strategic partnerships and collaborations with other industry players. The cancellation of existing agreements will allow Bright Green to forge new partnerships that better align with the company's new direction and goals. Lynn Stockwell's extensive industry experience and network can open doors to new strategic partnerships. Her connections with established U.S. based drug manufacturers, as well as other industry players, can lead to collaborations that were not possible under the previous management. The new management's emphasis on domestic production will likely attract U.S.-based pharmaceutical companies looking to stay competitive in the politically driven manufacturing landscape. This could lead to partnerships focused on producing controlled substances in the United States.

In conclusion, Bright Green's restructuring and new focus on plant-based controlled substances present an attractive opportunity for investors. The company's strategic alignment with Lynn Stockwell's vision, combined with its existing expertise and registrations, positions it well to capitalize on the growing demand for domestic production of controlled substances. The cancellation of existing agreements and the new leadership's network and experience will play a significant role in shaping the company's strategic partnerships and collaborations. For investors who have high conviction in the company's business model, this could be an opportune time to add more positions, capitalizing on the market's potential undervaluation of the company's prospects.

Rating: Speculative Buy. Note: As with our cautious/speculative ratings, investors must consider appropriate risk management strategies, including pre-defined stop-loss/profit-taking targets, within an appropriate risk exposure.